| Individual therapy |
|
|
|
| MK-0752 (Merck and Co, Whitehouse Station, NJ, USA) |
Metastatic or locally advanced breast cancer |
Phase I |
NCT00106145 |
| PF03084014 (Pfizer, Groton, CT, USA) |
Advanced solid tumors |
Phase I |
NCT00878189 |
| RO-4929097 (Roche, Nutley, NJ, USA) |
Advanced or metastatic breast cancer or recurrent triple negative breast cancer |
Phase II |
NCT01151449 |
| Combination therapy |
|
|
|
| MK-0752 + docetaxel |
Locally advanced or metastatic breast cancer |
Phase I/II |
NCT00645333 |
| MK-0752 + tamoxifen or letrozole |
Early stage breast cancer |
Pilot study |
NCT00756717 |
| Ridaforolimus (MK-8669) with either MK-0752 or MK-2206 (Akt inhibitor) |
Advanced solid tumor |
Phase I |
NCT01295632 |
| RO-4929097 + capecitabine |
Refractory solid tumors |
Phase I |
NCT01158274 |
| RO-4929097 + cediranib maleate |
Advanced solid tumors |
Phase I clinical trial |
NCT01131234 |
| RO-4929097 + letrozole |
Post-menopausal ER+/PR+ stage I or II breast cancer |
Phase Ib clinical trial |
NCT01208441 |
| RO-4929097 + vismodegib |
Metastatic breast cancer |
Phase I clinical trial |
NCT01071564 |
| RO-4929097 + paclitaxel + carboplatin |
Stage II or III triple negative breast cancer |
Phase I clinical trial |
NCT01238133 |
